Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for AstraZeneca (LON:AZN) Stock

AstraZeneca (LON:AZN) had its target price hoisted by equities research analysts at Deutsche Bank Aktiengesellschaft from £117 to £120 in a research note issued on Friday, Digital Look reports. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft‘s price objective suggests a potential downside of 14.98% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. Berenberg Bank reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a report on Wednesday, October 7th. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a research report on Friday, October 30th. Finally, Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating and a £145 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of £155.50.

AstraZeneca Trading Up 1.3%

AZN opened at £141.15 on Friday. The firm’s 50 day moving average is £124.76 and its 200-day moving average is £134.29. AstraZeneca has a 52-week low of £114.04 and a 52-week high of £157.32. The company has a quick ratio of 0.59, a current ratio of 1.01 and a debt-to-equity ratio of 66.10. The firm has a market capitalization of £218.91 billion, a P/E ratio of 19.99, a P/E/G ratio of 0.86 and a beta of 0.21.

Insiders Place Their Bets

In related news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was bought at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.